Am J Neuroradiol:识别高灌注的DSA预警征象,精准血压管理

2019-10-29 杨中华 脑血管病及重症文献导读

66岁,女性。表现为左侧肢体一过性缺血的症状。

66岁,女性。

表现为左侧肢体一过性缺血的症状。

A 图,平扫 CT 显示右侧放射冠内分水岭区低密度,为陈旧性缺血性梗死。CTA 和 CT 灌注显示右侧MCA M1段严重狭窄。B 和 C 图为右侧 ICA 造影(成形术前和后),血管成形术和支架置入后显示血流恢复(箭头):



D 图,置入支架后立即造影(此时血压为158 mmHg),在动脉晚期可见静脉早期显影(opacification),引流到深部静脉(黑色箭头),同时在 MCA 中央区见显着毛细血管染色(blush)(黑色箭头)。开始积极降压治疗(包括镇静等),每10分钟重复造影,直到血压降低到 DSA前哨性征象消失。E 和 F 图为毛细血管和静脉期影像(收缩压100 mmHg)显示早期静脉分流消失,毛细血管均一染色恢复正常,在正常静脉期上述静脉充盈(filling):



上述两个前哨性征象提示动脉扩张到极限以及脑自主调节功能破坏,这会增加高灌注的风险:首先,经过治疗缺血区域的早期引流静脉,定义为动脉晚期或毛细血管期可见常规解剖静脉的早期造影剂充盈(filling)。其次,缺血区域显着毛细血管染色(blush)是动脉期继发于治疗区域异常奢侈灌注,在毛细血管期变得更加浓密。

作者认为该患者手术后24h 的最佳血压目标应该为100 mmHg。

原始出处:M. Ghuman, A.C.O. Tsang, J.M. Klostranec and T. Krings. Sentinel Angiographic Signs of Cerebral Hyperperfusion after Angioplasty and Stenting of Intracranial Atherosclerotic Stenosis: A Technical Note. AJNR Am J Neuroradiol. 2019, 40 (9)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951227, encodeId=f020195122e13, content=<a href='/topic/show?id=44fd10249309' target=_blank style='color:#2F92EE;'>#高灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102493, encryptionId=44fd10249309, topicName=高灌注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Jul 17 12:48:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344331, encodeId=ac1b134433162, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361464, encodeId=66951361464f2, content=<a href='/topic/show?id=068a62e790' target=_blank style='color:#2F92EE;'>#DSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6277, encryptionId=068a62e790, topicName=DSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403460, encodeId=e33314034600c, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951227, encodeId=f020195122e13, content=<a href='/topic/show?id=44fd10249309' target=_blank style='color:#2F92EE;'>#高灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102493, encryptionId=44fd10249309, topicName=高灌注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Jul 17 12:48:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344331, encodeId=ac1b134433162, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361464, encodeId=66951361464f2, content=<a href='/topic/show?id=068a62e790' target=_blank style='color:#2F92EE;'>#DSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6277, encryptionId=068a62e790, topicName=DSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403460, encodeId=e33314034600c, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951227, encodeId=f020195122e13, content=<a href='/topic/show?id=44fd10249309' target=_blank style='color:#2F92EE;'>#高灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102493, encryptionId=44fd10249309, topicName=高灌注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Jul 17 12:48:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344331, encodeId=ac1b134433162, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361464, encodeId=66951361464f2, content=<a href='/topic/show?id=068a62e790' target=_blank style='color:#2F92EE;'>#DSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6277, encryptionId=068a62e790, topicName=DSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403460, encodeId=e33314034600c, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
    2019-10-30 zhmscau
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951227, encodeId=f020195122e13, content=<a href='/topic/show?id=44fd10249309' target=_blank style='color:#2F92EE;'>#高灌注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102493, encryptionId=44fd10249309, topicName=高灌注)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri Jul 17 12:48:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344331, encodeId=ac1b134433162, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361464, encodeId=66951361464f2, content=<a href='/topic/show?id=068a62e790' target=_blank style='color:#2F92EE;'>#DSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6277, encryptionId=068a62e790, topicName=DSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e94174, createdName=zhmscau, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403460, encodeId=e33314034600c, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Wed Oct 30 18:48:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]

相关资讯

国内III期肺癌规范化诊疗示范中心正式成立,精准助力III期肺癌规范化诊疗

2019年9月14日,由中国科学院大学附属肿瘤医院(浙江省肺癌诊治技术研究中心)在全国范围内率先开设的“III期肺癌规范化诊疗示范中心”正式成立,并于9月20日正式挂牌。这是国内首个专门针对III期肺癌成立的诊疗示范中心,将会推动中国III期肿瘤的规范化诊疗进程,有效把握III期这一治疗 “关键窗口期”,助力更多的患者治愈肿瘤,重现绽放!

nature:研究表明基因“剪刀”并没那么精准

研究人员一直对CRISPR基因编辑技术作为一种改变基因组的方法持欢迎态度,但一些人警告说,不需要的DNA改变可能会在未察觉的情况下溜进来。

沪疆合作远程精准指导微创手术救治先心病患儿

11月28日,专门为此次手术前往新疆的复旦大学附属儿科医院胸外科副主任医师陈纲通过视频向复旦大学附属儿科医院心血管中心主任贾兵教授(右二)汇报术前准备情况。

Sci Trans Med:“肿瘤粘扣”可助精准抗癌

美国麻省理工学院研究人员发现一种特殊蛋白质能像“肿瘤粘扣”一样,把具有抗癌作用的细胞因子“粘”在肿瘤组织中,提升抗癌效果,未来有望在此基础上开发新型的精准抗癌疗法。

Sensors:数字PET在线精准监测质子治疗研究获新突破

质子放疗是最尖端的癌症放疗技术之一,人称“治癌利器”。近日,华中科技大学谢庆国团队运用自主研发的平板全数字PET首次监测到了质子束打到人体组织上产生的氧15,说明数字PET极有可能实现对质子束β+衰变产生的正电子发射核分布情况的精准监测,从而追踪到质子束的投递剂量和作用范围。

肿瘤诊治如何才能“精准”?原来全靠这些办法

肿瘤的过度诊疗一直是大众关注和讨论的话题。人们希望通过适度的筛查手段就能做到肿瘤的早发现、早诊断和早治疗,从而取得较好的疗效;希望采用适度的检查来全面评估病情,希望以“最小的治疗”取得“最大的获益”。肿瘤专家表示,我国肿瘤防治在“精准”与“过度”之间寻找平衡。老百姓不要被网络言论带偏,癌症防治不能因噎废食。